Citalopram Treatment for Impulsive Aggression in Children and Adolescents

An Open Pilot Study

Jorge L. Armenteros, John E Lewis

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: To assess the short-term effect and safety of citalopram in the reduction of impulsive aggression in children and adolescents. Method: Twelve subjects, aged 7 to 15 years, were attending a psychiatric outpatient clinic and had a profile of impulsive aggression. Subjects were treated in an open trial with citalopram for 6 weeks after a 1-week washout period. Dosage was regulated individually over a period of 4 weeks. The starting dose was 10 mg/ day followed by 10 mg increments on a weekly basis. The maximum dose was not to exceed 40 mg/day. Outcome measures included the Modified Overt Aggression Scale (MOAS), the Child Behavioral Checklist (CBCL), and the Clinical Global Impressions (CGI). Results: Eleven subjects completed the study. Citalopram produced clinically and statistically significant reductions on target symptoms of impulsive aggression, independent of other behavioral problems, as measured by the MOAS, the CBCL, and the CGI at doses ranging from 20 to 40 mg/day (mean = 27 mg). No major adverse reactions were associated with citalopram use. Conclusion: Citalopram appears to be effective and well tolerated in this sample of children and adolescents with impulsive aggression.

Original languageEnglish
Pages (from-to)522-529
Number of pages8
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume41
Issue number5
DOIs
StatePublished - May 1 2002

Fingerprint

Citalopram
Aggression
Checklist
Therapeutics
Ambulatory Care Facilities
Psychiatry
Outcome Assessment (Health Care)
Safety

Keywords

  • Citalopram
  • Impulsive aggression
  • Psychopharmacology

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Citalopram Treatment for Impulsive Aggression in Children and Adolescents : An Open Pilot Study. / Armenteros, Jorge L.; Lewis, John E.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 41, No. 5, 01.05.2002, p. 522-529.

Research output: Contribution to journalArticle

@article{36d69cd042af405ea76fb1b457b78c08,
title = "Citalopram Treatment for Impulsive Aggression in Children and Adolescents: An Open Pilot Study",
abstract = "Objective: To assess the short-term effect and safety of citalopram in the reduction of impulsive aggression in children and adolescents. Method: Twelve subjects, aged 7 to 15 years, were attending a psychiatric outpatient clinic and had a profile of impulsive aggression. Subjects were treated in an open trial with citalopram for 6 weeks after a 1-week washout period. Dosage was regulated individually over a period of 4 weeks. The starting dose was 10 mg/ day followed by 10 mg increments on a weekly basis. The maximum dose was not to exceed 40 mg/day. Outcome measures included the Modified Overt Aggression Scale (MOAS), the Child Behavioral Checklist (CBCL), and the Clinical Global Impressions (CGI). Results: Eleven subjects completed the study. Citalopram produced clinically and statistically significant reductions on target symptoms of impulsive aggression, independent of other behavioral problems, as measured by the MOAS, the CBCL, and the CGI at doses ranging from 20 to 40 mg/day (mean = 27 mg). No major adverse reactions were associated with citalopram use. Conclusion: Citalopram appears to be effective and well tolerated in this sample of children and adolescents with impulsive aggression.",
keywords = "Citalopram, Impulsive aggression, Psychopharmacology",
author = "Armenteros, {Jorge L.} and Lewis, {John E}",
year = "2002",
month = "5",
day = "1",
doi = "10.1097/00004583-200205000-00009",
language = "English",
volume = "41",
pages = "522--529",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Citalopram Treatment for Impulsive Aggression in Children and Adolescents

T2 - An Open Pilot Study

AU - Armenteros, Jorge L.

AU - Lewis, John E

PY - 2002/5/1

Y1 - 2002/5/1

N2 - Objective: To assess the short-term effect and safety of citalopram in the reduction of impulsive aggression in children and adolescents. Method: Twelve subjects, aged 7 to 15 years, were attending a psychiatric outpatient clinic and had a profile of impulsive aggression. Subjects were treated in an open trial with citalopram for 6 weeks after a 1-week washout period. Dosage was regulated individually over a period of 4 weeks. The starting dose was 10 mg/ day followed by 10 mg increments on a weekly basis. The maximum dose was not to exceed 40 mg/day. Outcome measures included the Modified Overt Aggression Scale (MOAS), the Child Behavioral Checklist (CBCL), and the Clinical Global Impressions (CGI). Results: Eleven subjects completed the study. Citalopram produced clinically and statistically significant reductions on target symptoms of impulsive aggression, independent of other behavioral problems, as measured by the MOAS, the CBCL, and the CGI at doses ranging from 20 to 40 mg/day (mean = 27 mg). No major adverse reactions were associated with citalopram use. Conclusion: Citalopram appears to be effective and well tolerated in this sample of children and adolescents with impulsive aggression.

AB - Objective: To assess the short-term effect and safety of citalopram in the reduction of impulsive aggression in children and adolescents. Method: Twelve subjects, aged 7 to 15 years, were attending a psychiatric outpatient clinic and had a profile of impulsive aggression. Subjects were treated in an open trial with citalopram for 6 weeks after a 1-week washout period. Dosage was regulated individually over a period of 4 weeks. The starting dose was 10 mg/ day followed by 10 mg increments on a weekly basis. The maximum dose was not to exceed 40 mg/day. Outcome measures included the Modified Overt Aggression Scale (MOAS), the Child Behavioral Checklist (CBCL), and the Clinical Global Impressions (CGI). Results: Eleven subjects completed the study. Citalopram produced clinically and statistically significant reductions on target symptoms of impulsive aggression, independent of other behavioral problems, as measured by the MOAS, the CBCL, and the CGI at doses ranging from 20 to 40 mg/day (mean = 27 mg). No major adverse reactions were associated with citalopram use. Conclusion: Citalopram appears to be effective and well tolerated in this sample of children and adolescents with impulsive aggression.

KW - Citalopram

KW - Impulsive aggression

KW - Psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=0036581264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036581264&partnerID=8YFLogxK

U2 - 10.1097/00004583-200205000-00009

DO - 10.1097/00004583-200205000-00009

M3 - Article

VL - 41

SP - 522

EP - 529

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 5

ER -